Special Issue "Discovery of Glucosidase Inhibitors and Other Targets as Potential Antidiabetic Agents"
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: 30 November 2023 | Viewed by 351
Special Issue Editors
.JPG)
Interests: pharmacognosy of Mexican medicinal plants; diabetes mellitus; cancer; diarrhea; molecular docking; secondary metabolites
Special Issues, Collections and Topics in MDPI journals
Interests: pharmacology; pharmacognosy; phytochemistry; medicinal plants; diabetes mellitus; cancer; diarrhea; drug development; isolation of natural compounds; terpenoids; flavonoids; molecular docking; molecular mechanism elucidation; pharmacological evaluation of natural compounds isolated from plants used in traditional Mexican medicine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Diabetes mellitus (DM) is a metabolic condition defined by chronically high blood sugar levels. This disease affected 537 million people globally in 2021, with this figure expected to rise to 643 million by 2030. Moreover, DM was found to be the ninth major cause of mortality in a worldwide study conducted by the World Health Organization. Hyperglycemia can lead to a variety of complications, such as cardiovascular disease, neuropathy, renal failure, lipid metabolism issues and many others.
One of the principal approaches to reducing postprandial hyperglycemia in patients with DM is the prevention of hydrolysis and the absorption of carbohydrates after food uptake via effective control of blood glucose levels, which represents a key step in preventing or reversing diabetic complications and improving the quality of life of diabetic patients. This is accomplished by suppressing the carbohydrate-hydrolyzing enzymes α-glucosidase and α-amylase in the digestive system, thus preventing glucose absorption. As a result, inhibitors of these enzymes slow the absorption of glucose and dampen the postprandial plasma glucose spike. Glucosidase inhibitors are considered a safe class of drugs, since their long-term use does not generate significant adverse effects for the patient who uses them.
In this Special Issue, we aim to draw together research from experts in the field, with the objective of discovering new drugs for the treatment of DM focused on the inhibition of glucosidases and other therapeutic targets.
Dr. Fernando Calzada
Dr. Miguel Valdes
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- diabetes mellitus
- diabetes complications
- glucosidase inhibitors
- antidiabetic agents
- molecular mechanism
- new drug development
- pharmacology
- molecular docking assays
